Research Article | Published:

Polymerizable Fab′ antibody fragments for targeting of anticancer drugs

Nature Biotechnology volume 17, pages 11011104 (1999) | Download Citation

Subjects

Abstract

We have designed a new pathway for the synthesis of targeted polymeric drug delivery systems, using polymerizable antibody Fab′ fragments (MA-Fab′). The targeted systems can be directly prepared by copolymerization of the MA-Fab′, N-(2-hydroxypropyl)methacrylamide (HPMA) and drug-containing monomers. Both MA-Fab′ and the Fab′-targeted copolymers can effectively bind to target cells. An MA-Fab′ (from OV-TL 16 Ab) targeted HPMA copolymer containing mesochlorin e6 (Mce6) was synthesized by copolymerization of MA-Fab′, HPMA, and MA-GFLG-Mce6. The targeted copolymer exhibited a higher cytotoxicity toward OVCAR-3 human ovarian carcinoma cells than the nontargeted Mce6-containing copolymer or free Mce6. The targeted copolymer was internalized more efficiently by OVCAR-3 cells than the nontargeted copolymer.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122, 55– 123 (1995).

  2. 2.

    , & Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vitro. Bioconjugate Chem . 3, 351–362 (1992).

  3. 3.

    et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents—drug–polymer conjugates. Clin. Cancer Res. 5, 83– 94 (1999).

  4. 4.

    et al. Novel perspectives in topoiosmerase-I inhibitor-based chemotherapy of solid tumors: MAG-camptothecin conjugates. Abstr. Ninth Intl. Symp. Recent Adv. Drug Delivery Systems. Salt Lake City, UT, February 22, 1999, p. 46.

  5. 5.

    Biorecognition of antibodies in vivo: potential in drug targeting. J. Mol. Recognition 9, 309–315 (1996).

  6. 6.

    , , , , & HPMA copolymer–anticancer drug–OV-TL 16 antibody conjugates. 1. Influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J. Drug Targeting 3, 357–373 (1996).

  7. 7.

    et al. Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol. 46, 100–114 (1988).

  8. 8.

    et al. Phase-separation immunoassays. Clin. Chem. 33, 1509–1516 (1987).

  9. 9.

    & A novel immunoassay system and bioseparation process based on thermal phase separating polymers. Appl. Biochem. Biotech. 14, 107–119 (1987).

  10. 10.

    , , & Approaches to improved antibody- and peptide-mediated targeting for imaging and therapy of cancer. J. Controlled Release 28, 167–173 (1994).

  11. 11.

    et al. Comparative in vitro binding and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies. Anticancer Res. 10, 1289–1296 (1990).

  12. 12.

    et al. Monoclonal antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids. Anticancer Res. 9, 551–558 (1989).

  13. 13.

    , & Polymerizable Fab' antibody fragments. Proc. Intl. Symp. Controlled Release Bioactive Mater. 25, 788–789 (1998).

  14. 14.

    On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from Balb/c mice. J. Immunol. 131, 2895–2902 (1993).

  15. 15.

    , , , & Monoclonal antibodies: purification, fragmentation and application to structural and functional studies of class I MHC antigens. J. Immunol. Methods 53, 133–173 (1982).

  16. 16.

    et al. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl)methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res. 56, 3980– 3985 (1996).

  17. 17.

    , , , & Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 184, 2009–2020 (1983).

  18. 18.

    , , & HPMA copolymer–anticancer drug–OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer 75, 600–608 (1998).

  19. 19.

    et al. Enhanced tumor specificity of an anticarcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. Br. J. Cancer 73, 175–182 (1996).

  20. 20.

    et al. Enzymatic cleavage of side chains of synthetic water-soluble polymers. Makromol. Chem. 177, 2833– 2848 (1976).

  21. 21.

    & Poly[N-(2-hydroxypropyl)methacrylamide]. 1. Radical polymerization and copolymerization. Eur. Polym. J. 9, 7–14 (1973 ).

  22. 22.

    et al. Synthetic polymeric drugs. U.S. Pat. 5,037,883 (Aug. 6, 1991).

Download references

Acknowledgements

We thank Dr. L. Poels (University of Nijmegen, The Netherlands) for the generous gift of the hybridoma producing OV-TL 16 antibody, and Dr. Z. Wu for collecting the MALDI-TOF mass spectra of the antibody and its fragments. This research was supported in part by NIH grant CA51578 from the National Cancer Institute, and by the Center for Biopolymers at Interfaces, University of Utah.

Author information

Affiliations

  1. Departments of Pharmaceutics and Pharmaceutical Chemistry/CCCD, and of Bioengineering, University of Utah, Salt Lake City, UT 84112.

    • Zheng-Rong Lu
    • , Pavla Kopečková
    •  & Jindřich Kopeček

Authors

  1. Search for Zheng-Rong Lu in:

  2. Search for Pavla Kopečková in:

  3. Search for Jindřich Kopeček in:

Corresponding author

Correspondence to Jindřich Kopeček.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/15085

Further reading